All In Biotech

NDA 205395 · Janssen Prods

Prezcobix

Cobicistat, Darunavir Ethanolate · Oral · Cytochrome P450 3A Inhibitor

Priority review

Last checked: Nov 20, 2026Latest source record: Feb 27, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

Jan 29, 2015

Approved uses

5

Original approval plus efficacy supplements

Registered trials

155

48 Phase 3, 6 recruiting

FAERS reports

1,762

1,152 serious, 136 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 1, 2026.

PREZCOBIX and PREZCOBIX PED are indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) in treatment-naïve and treatment-experienced adults and pediatric patients 3 years of age and older weighing at least 15 kg with no darunavir resistance-associated substitutions (V11I, V32I, L33F, I47V, I50V, I54L, I54M, T74P, L76V, I84V, L89V) [see Use in Specific Populations (8.4) and Clinical Studies (14) ] . PREZCOBIX and PREZCOBIX PED are a two-drug combination of darunavir, a human immunodeficiency virus (HIV-1) protease inhibitor, and cobicistat, a CYP3A inhibitor, and are indicated for the treatment of HIV-1 in treatment-naïve and treatment-experienced adults and pediatric patients 3 years of age and older weighing at least 15 kg with no darunavir resistance-associated substitutions (V11I, V32I, L33F, I47V, I50V, I54L, I54M, T74P, L76V, I84V, L89V). ( 1 )

Mechanism: PREZCOBIX and PREZCOBIX PED are fixed-dose combinations of an HIV-1 antiviral drug, darunavir and a CYP3A inhibitor, cobicistat [see Microbiology (12.4) ].

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 27, 2026 Supplement 29 · Efficacy LetterLabel
  • Mar 21, 2025 Supplement 28 · Efficacy LabelLetter
  • Jul 31, 2020 Supplement 16 · Efficacy LetterLabel
  • Jun 4, 2018 Supplement 9 · Efficacy · priority review LabelLetter
  • Jan 29, 2015 Original approval · Type 4 - New Combination · priority review LabelReviewLetter
2 products under this application
  • PREZCOBIX · COBICISTAT 150MG; DARUNAVIR ETHANOLATE EQ 675MG BASE · TABLET, ORAL · Prescription
  • PREZCOBIX · COBICISTAT 150MG; DARUNAVIR ETHANOLATE EQ 800MG BASE · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Cobicistat" as an intervention, any sponsor and status, largest first.

All 155 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pain440
  • emotional distress426
  • anxiety404
  • anhedonia377
  • chronic kidney disease256
  • osteoporosis181
  • bone density decreased170
  • renal failure170
  • depression147
  • economic problem138
  • fatigue135
  • acute kidney injury131

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20131
201569
2016111
2017194
2018211
2019289
2020284
2021170
2022123
2023113
202497
202565
202635

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Prezcobix (Darunavir/Cobicistat)

2024 spending

$255M

Beneficiaries

11,230

99,872 claims

Per beneficiary

$22,742

$81.22 per unit

View as table
YearSpending
2020$268,321,186
2021$261,899,585
2022$265,352,859
2023$271,838,024
2024$255,398,075

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 156 on PubMed

Sponsor: Johnson & Johnson (Janssen)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.